Thermal Ablation: How It Works and What It Treats

Thermal ablation destroys targeted tissue by delivering extreme temperatures, either intense heat or freezing cold, directly into a tumor or other unwanted growth through a needle-like probe. The technique has become a mainstay in treating liver, kidney, and lung cancers, and it now extends well beyond oncology into cardiac arrhythmias, thyroid nodules, uterine fibroids, and painful bone metastases. Because the energy is focused at the probe tip, the surrounding healthy tissue is largely spared, which makes thermal ablation an option for patients who cannot tolerate open surgery or whose anatomy makes traditional operations risky.

How Heat and Cold Destroy Cells

All thermal ablation methods share a goal: raise or lower tissue temperature enough to kill cells irreversibly. The three most widely used modalities each get there differently.

• Radiofrequency ablation (RFA): An alternating electrical current flows from the tip of an electrode into the tissue, causing ions to vibrate and generate frictional heat. Temperatures climb high enough to denature proteins inside cells, which kills them.¹
• Microwave ablation (MWA): A generator sends electromagnetic microwaves through an antenna. Those waves agitate water molecules in the tissue, producing friction and heat that cause coagulation necrosis, essentially cooking the cells until they die.²
• Cryoablation: Instead of heat, a cryoprobe circulates an extremely cold gas (often argon) to freeze tissue. Cell damage comes from two routes: ice crystals that physically rupture cell membranes, and changes to blood supply around the frozen zone that starve surviving cells of oxygen. How fast the tissue cools, how cold it gets, how long it stays cold, and how quickly it thaws all influence how complete the destruction is.³

Microwave ablation heats tissue faster and can produce larger zones of destruction than RFA, which makes it increasingly popular for bigger tumors. Cryoablation has a distinct advantage in that the ice ball forming at the probe tip is visible on imaging during the procedure, giving the operator real-time feedback on how much tissue is being treated. RFA remains the longest-studied and most widely available of the three.

Liver Cancer

The liver is where thermal ablation has its deepest evidence base. For early-stage hepatocellular carcinoma, the most common primary liver cancer, RFA and surgical removal have been compared head-to-head in multiple trials. A meta-analysis pooling data from randomized trials and high-quality matched studies found that for single tumors smaller than about 3 cm, RFA produced overall survival rates similar to surgical resection. Disease-free survival still favored surgery, but that gap narrowed when ablation margins were adequate: with a margin larger than 1 cm around the tumor, the two approaches delivered comparable outcomes.⁴

Imaging guidance plays a central role during liver ablation. Most procedures are performed under ultrasound, CT, or a combination of both, so the operator can see the probe in relation to the tumor in real time. A study comparing standard ultrasound-guided ablation with fusion imaging, which overlays CT or MRI data onto a live ultrasound feed, found three-year local recurrence-free survival rates around 78% for ultrasound guidance alone and roughly 90% for fusion-guided ablation, though after statistical matching the difference was not significant.⁵ Even so, fusion imaging is gaining ground for tumors that are hard to spot on ultrasound alone.

Cost matters here too. An economic analysis found that for very early liver cancer (a single nodule under 2 cm) in patients with well-preserved liver function, RFA provided life expectancy and quality-adjusted life expectancy similar to surgery, at lower cost. RFA was the most cost-effective strategy in that scenario, and it remained favorable even for patients with two or three small nodules.⁶

Kidney Tumors

Small kidney tumors, often discovered incidentally on scans done for other reasons, are a natural fit for thermal ablation. Unlike partial nephrectomy (removing the tumor surgically while preserving the rest of the kidney), ablation treats the tumor in place without clamping blood flow to the kidney. That distinction matters for kidney function: patients who need to keep every bit of working kidney tissue, particularly those with only one functioning kidney or with pre-existing kidney disease, tend to have better long-term kidney function after ablation than after surgery.⁷

Thermal ablation also works as a salvage treatment. A study of patients whose kidney tumors recurred in the same kidney after previous partial nephrectomy showed that percutaneous ablation achieved local oncologic control in about 95% of cases, with a five-year recurrence-free survival above 93%. Recurrences in the ablation zone were uncommon, occurring in roughly 5% of cases and typically detected within the first year.⁸ For patients already down one kidney or part of one, avoiding a second surgery can be meaningful.

Lung Cancer and Bone Metastases

Percutaneous ablation of early-stage non-small cell lung cancer has proven safe and effective for patients who are not surgical candidates, whether because of poor lung function, advanced age, or other medical conditions.⁹ Both RFA and microwave ablation have been used for stage I lung cancers, and a comparative study found their outcomes in terms of effectiveness, safety, and prognosis were comparable.¹⁰ Lung ablation does carry some unique procedural risks, notably pneumothorax (air leaking from the lung into the chest cavity around the puncture site), but this is usually managed with a small chest tube if it occurs.

Bone metastases represent a different use case: here the goal is not cure but pain relief. When cancer spreads to bone, the resulting pain can be severe and poorly controlled by medication alone. A systematic review and meta-analysis of RFA and cryoablation for painful bone metastases found that both modalities significantly reduced pain at every follow-up time point measured.¹¹ A multicenter study of 100 patients treated with RFA for bone metastases reported that average worst pain scores dropped from about 8 out of 10 at baseline to roughly 3.5 at six months, with significant improvements in daily function and quality of life as well.¹² Most bone ablation procedures are followed by cementoplasty, where bone cement is injected to stabilize the weakened area.

Uses Beyond Cancer

Thermal ablation has carved out a large role in cardiology. Catheter ablation for atrial fibrillation, the most common sustained heart rhythm disorder, works by electrically isolating the pulmonary veins from the left atrium. These veins are often the source of the erratic electrical signals that trigger the arrhythmia. Catheter ablation has been shown to be superior to antiarrhythmic drugs for maintaining a normal heart rhythm.¹³ Both heat-based (radiofrequency) and cold-based (cryo) catheters are used. Cryoablation in the heart has a particular safety advantage: it carries virtually no risk of pulmonary vein stenosis, a narrowing that can complicate heat-based ablation near those delicate structures. One study reported clinically satisfactory results in about 71% of atrial fibrillation patients treated with catheter cryoablation, with no cases of vein stenosis.¹⁴

Benign thyroid nodules are another growing application. Large nodules can cause visible swelling in the neck, a feeling of pressure, or difficulty swallowing, but many patients prefer to avoid thyroid surgery because of the risk of permanent hormone dependence. Thermal ablation shrinks these nodules without removing the gland. A study of patients treated with ablation, including some who had already undergone previous thyroid surgery, found that both symptom and cosmetic scores improved significantly, while thyroid hormone levels remained unchanged from before treatment.¹⁵ Preserving normal thyroid function is the key draw here.

Uterine fibroids round out the non-cancer applications. Radiofrequency ablation of fibroids is an outpatient, uterus-sparing procedure that has received FDA clearance. Clinical trial data have shown both resolution or improvement of symptoms and significant reduction in fibroid volume. Recovery tends to be fast, typically requiring only over-the-counter pain relievers afterward.¹⁶ For patients who want to preserve their uterus, whether for future fertility or personal preference, ablation fills a gap between medication and hysterectomy.

The Heat Sink Problem

One of the most important limitations of thermal ablation is something called the heat sink effect. When a tumor sits next to a large blood vessel, the flowing blood acts like a radiator: it carries heat away from the ablation zone before the tissue can reach a lethal temperature. The result is an incomplete kill zone with a dent or invagination on the side facing the vessel.¹⁷

The effect scales with vessel size. An experimental study in pig livers found that the heat sink effect appeared in about 73% of veins larger than 3 mm but in none of the veins smaller than 3 mm. All small vessels showed at least partial wall injury from the heat, but larger vessels increasingly resisted damage, with every vein over 5 mm showing viable tissue clinging to its wall.¹⁸ This is why tumors nestled against major hepatic veins or the portal vein are considered challenging targets for ablation.

The phenomenon is not limited to the liver. An ex vivo thyroid model demonstrated that as simulated blood flow rates increased, the ablation zone shrank meaningfully, regardless of the power level used.¹⁹ Microwave ablation is somewhat less susceptible to this effect than RFA because microwaves heat tissue more aggressively and reach higher temperatures, but no thermal method eliminates it entirely. Operators account for the heat sink by adjusting probe placement, increasing power, or sometimes performing multiple overlapping ablations.

What the Procedure Feels Like

A common question for anyone facing thermal ablation is how much it hurts and whether they will be awake. The answer depends on what is being treated and where. Practice varies widely: some patients receive only local anesthesia at the skin puncture site, others get intravenous sedation, and some undergo full general anesthesia.²⁰ Tumor location is the biggest factor. Liver ablation near the diaphragm or liver capsule tends to be more painful than ablation deep inside the liver parenchyma, because the capsule and diaphragm are rich in pain fibers.

For liver ablation specifically, local anesthesia and general anesthesia have been compared and shown to produce similar rates of post-procedure complications like pain, fever, and nausea.²¹ The choice comes down partly to patient comfort and partly to whether the patient needs to hold their breath on command for precise imaging. A comparison of sedation protocols found that midazolam-based sedation produced significantly worse pain during and immediately after treatment compared to propofol sedation or general anesthesia.²² If you are offered a choice, it is worth asking about propofol-based sedation, which appears to offer better intra-procedural comfort.

Complications from ablation itself are generally tied to thermal damage near the probe, direct needle injury, infection, or interactions with a patient’s existing health problems.²³ Major complications are uncommon, but they include bleeding, injury to neighboring organs, and abscess formation. Most patients go home the same day or after one night in the hospital.

Cost and Recovery Compared to Surgery

For small thyroid cancers, a meta-analysis comparing thermal ablation with surgery found that ablation shortened both operating time and hospital stay, cost less, and resulted in fewer postoperative complications.²⁴ The pattern holds in the liver as well: for very early hepatocellular carcinoma, RFA was the most cost-effective option over a ten-year horizon, delivering equivalent quality-adjusted survival to surgical resection at lower cost.⁶ These advantages are driven by the minimally invasive nature of ablation: a single puncture through the skin, no large incision, minimal blood loss, and faster return to normal activity.

That said, ablation is not always the cheaper or better choice. Larger tumors, tumors in tricky locations near critical structures, and cancers that have spread to lymph nodes usually call for surgery, radiation, or systemic therapy. Ablation’s sweet spot is small, accessible tumors in patients who either cannot tolerate bigger operations or whose disease is caught early enough that a focal treatment can handle it.

Nonthermal Alternatives

The heat sink problem and the risk of thermal injury to nearby structures have driven interest in nonthermal ablation methods, the most prominent being irreversible electroporation (IRE). IRE uses short, high-voltage electrical pulses to punch permanent holes in cell membranes, killing cells without relying on temperature at all. Preclinical work has shown that IRE can destroy substantial volumes of liver tissue without the heat sink effect and with remarkable preservation of blood vessels, bile ducts, and other structural scaffolding within the ablation zone.²⁵ In animal studies, histology performed four weeks after IRE showed that blood vessel walls lost most of their smooth muscle cells but the connective framework remained intact, with no signs of aneurysm, clot formation, or tissue death in the vessel itself.²⁶

IRE has its own downsides. It requires general anesthesia with muscle relaxation because the electrical pulses cause involuntary muscle contractions. Treatment times are longer, and the technique is sensitive to cardiac rhythm, requiring synchronization of pulses to the heartbeat to avoid triggering arrhythmias. For now, IRE occupies a niche for tumors that sit too close to major vessels or bile ducts for thermal ablation to be safe, rather than replacing heat- or cold-based methods across the board.

Ablation and the Immune System

When thermal ablation destroys a tumor, the debris left behind contains proteins and other molecules unique to the cancer. In theory, the immune system can recognize these fragments and mount a response not only against residual local disease but also against distant metastases, a phenomenon sometimes called the abscopal effect. Research into combining ablation with immune checkpoint blockers, drugs that remove the brakes on immune cells, is exploring whether ablation can act as an in-body vaccine of sorts.²⁷

A ten-year single-center study of patients who received thermal ablation alongside checkpoint immunotherapy found that the combination was feasible and well tolerated, with most procedure-related complications graded as mild. In four cases, a tumor distant from the one that was ablated shrank over the following six months, despite no change in the drug regimen. The investigators attributed this to an immune response triggered by the ablation itself.²⁷ Four cases out of a larger cohort is far from proof, but it is the kind of signal that has prompted randomized trials now underway. If the combination pans out, ablation could shift from a purely local treatment to one that primes a bodywide anticancer response, an idea that would have seemed fanciful a decade ago but is taken seriously in oncology today.